ArriVent Lead Drug Candidate Exhibits Promise In Lung Most cancers Kind, Analyst Sees Over 50% Upside – ArriVent BioPharma (NASDAQ:AVBP)

B. Riley Securities initiated protection on Wednesday on ArriVent Biopharma, Inc. AVBP, a clinical-stage biopharmaceutical centered on growing most cancers remedy.

The corporate’s lead drug candidate, firmonertinib is presently being studied in a world FURVENT Section 3 trial for first-line non-small cell lung most cancers (NSCLC) sufferers with EGFR exon 20 insertion mutations and in a world Section 1b research, which features a cohort evaluating firmonertinib in sufferers with epidermal development issue receptor (EGFR) P-loop and alpha-c helix compressing (PACC) mutations.

Additionally Learn: Elevation Oncology Stops Gastric Most cancers Research, Slashes Employees By 70%

As well as, firmonertinib can also be being studied in a medical mixture research focusing on superior or metastatic NSCLC sufferers with EGFR classical mutations.

In September 2024, ArriVent introduced interim Section 1b information for first-line firmonertinib monotherapy in NSCLC sufferers with EGFR PACC mutations. The info demonstrated sturdy systemic and CNS anti-tumor exercise with a manageable security profile.

The B. Riley analyst writes firmonertinib is designed to sort out NSCLC with EGFR exon 20 insertion (ex20ins) and PACC mutation — a market that accounts for ~4% of all NSCLC circumstances.

Analyst Kalpit Patel estimates firmonertinib may function a superior remedy within the potential ~$700 million/12 months marketplace for ex20ins NSCLC with three key benefits, particularly oral administration, mind penetration and higher tolerability.

With a Section 3 medical catalyst anticipated this 12 months for ex20ins NSCLC, B. Riley sees the potential for 50%–100% upside forward if the pivotal research replicates prior information.

The analyst initiated with a Purchase ranking and a value goal of $37.

“Whereas buyers are possible centered on ex20ins NSCLC close to time period, we consider enlargement into PACC mutations represents a considerably undervalued alternative, as these account for ~12% of all EGFR mutations,” the analyst writes.

Analyst Patel provides that though ~40% of mutations are adequately handled with Boehringer Ingelheim’s Gilotrif (afatinib), the opposite 60% use chemotherapy, which provides restricted medical profit.

B. Riley writes that firmonertinib is presently the one EGFR TKI with demonstrated exercise throughout a broad spectrum of PACC mutations, together with frequent and uncommon subtypes.

“We consider firmonertinib is effectively positioned towards competing EGFR inhibitors in each ex20ins and PACC NSCLC,” B. Riley notes.

The corporate ended 2024 with money and money equivalents of $266.5 million.

AVBP Value Motion: ArriVent Biopharma inventory is up 0.56% at $19.71 at publication Thursday.

Learn Subsequent:

Picture: Shutterstock